Use of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) in Rare Anemia
AssigneeKind Pharmaceutical
InventorsShaojiang Deng, Dong Liu, Min Xiong, Jiang Liu
Life of this patent
Estimating the term…
Abstract
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
Claims16
A method for treating a rare anemia, comprising administering to a patient in need thereof a therapeutically effective amount of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI).
A method for increasing red blood cell count, hemoglobin levels, and/or hematocrit in a rare anemia, comprising administering to a patient in need thereof a therapeutically effective amount of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI).
Dependencies are inferred from the claim text.